Hepatosplenic and kidneys candidasis complicating an acute myeloblastic leukemia. A case treated with voriconazole and caspofungin;Candidose hépato-spléno-rénale compliquant une leucémie aiguë myéloblastique. À propos d'un cas traité par l'association voriconazole et caspofungine

Annales de Biologie Clinique

Volumn 63, Issue 4, 2005, Pages 423-427

  Elouennass, M ^a,b   Doghmi, K ^a,c   Fagot, T ^a   Soler, C ^a   Mac Nab, C ^a   Foissaud, V ^a   De Revel, T ^a   Herve V ^a  

^a PERCY MILITARY HOSPITAL   (France)

^b Service de Microbiologie   (Morocco)

^c Service d'Hématologie   (Morocco)

Author keywords

Acute leukemia; Candidiasis; Caspofungin; Voriconazole

Indexed keywords

ANTIFUNGAL AGENT; CASPOFUNGIN; CYCLOPEPTIDE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANDIDIASIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; KIDNEY DISEASE; LIVER DISEASE; MICROBIOLOGY; RADIOGRAPHY; SPLEEN DISEASE;

ADULT; ANTIFUNGAL AGENTS; CANDIDIASIS; FEMALE; HUMANS; KIDNEY DISEASES; LEUKEMIA, MYELOCYTIC, ACUTE; LIVER DISEASES; PEPTIDES, CYCLIC; PYRIMIDINES; SPLENIC DISEASES; TOMOGRAPHY, X-RAY COMPUTED; TRIAZOLES;

EID: 23644444003     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Anttila VJ, Elonen E, Nordling S, Sivonen A, Ruutu T, Ruutu P. Hepatosplenic candidiasis in patients with acute leukemia : incidence and prognostic implications. Clin Infect Dis 1997 ; 24 : 375-80.
2. Haron E, Feld R, Tuffnell P, et al. Hepatic candidiasis : an increasing problem in immunocompromised patients. Am J Med 1987 ; 83 : 17-26.
3. Sallah S, Smelka RC, Wehbie R, Sallah W, Nguyen NP, Vos P. Hepatosplenic candidiasis in patient with acute leukemia. Br J Haematol 1999 ; 106 : 697-701.
4. Sallah S. Hepatosplenic candidiasis in patients with acute leukemia, increasingly encountered complication. Anticancer Res 1999 ; 19 : 757-60.
5. Conférence de consensus. In : Prise en charge des candidoses et aspergilloses invasives (CI, AI) de l'adulte 13 mai 2004. SFAR, SPLIF, SRLF (SFH, SFMM, SFGM). Paris : Institut Pasteur, 2004.
6. Edwards JE, Bodey GP, Bowden RA, et al. International conference for the development of consensus o the management and prevention of severe candidal infections. Clin Infect Dis 1997 ; 25 : 43-59.
7. Armstrong D. Treatment of opportunistic fungal infections. Clin Infect Dis 1993 ; 16 : 1.
8. Rodriguez LJ, Rex JH, Anaissie EJ. Update on invasive candidiasis. Adv Pharmacol 1997 ; 37 : 349-400.
9. Viviani MA. Flucytosine - What is its future ? J Antimicrob Chemother 1995 ; 35 : 241-4.
10. Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections : results of a randomized, multicenter study of fluconazole versus amphotericin B and review of the litterature. Clin Infect Dis 1996 ; 23 : 964-72.
11. Mora-Duarte J, Betts R, Rotstein C, et al., Caspofungin invasive candidiasis study group. Comparaison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002 ; 347 : 2020-9.
12. Keating G, Figgit D. Caspofungin : a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis. Drugs 2003 ; 63 : 2235-63.
13. Petraitis V, Petraitiene R, Sarafandi AA, et al. Efficacy, safety, and plasma pharmacokinetics of PLD-118, a novel inhibitor of Candida isoleucyl-tRNA synthase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits. Program and abstracts of the 43rd annual ICAAC ; September 14-17, 2003 ; Chicago : abstract M-369.
14. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging or refractory fungal infections. Clin Infect Dis 2003 ; 36 : 1122-31.
15. Sora F, Chiusolo P, Piccirillo N, et al. Successful treatment with caspofungin of hepatosplenic candidiasis resistant to liposomal amphotericin B. Clin Infect Dis 2002 ; 35 : 1135-6.
16. Brown EA, Talbot GH. Focal hepatosplenic candidiasis. Infect Med 1991 ; 8 : 15-8.
17. Thaler M, Pastakia B, Shawker TH, O'Leary T, Pizzo PA. Hepatic candidiasis in cancer patients : the evolving picture of the syndrome. Ann Intern Med 1988 ; 108 : 88-100.
18. Tashjian LS, Abramson JS, Peacock JE. Focal hepatic candidiasis : a distinct clinical variant of candidiasis in immunocompromised patients. Rev Infect Dis 1984 ; 6 : 689-703.
19. Fujihara N, Saito T, Takakura S, et al. Evaluation of BACTEC mycosis IC/F blood culture bottle for recovery of fungi from blood. Program and abstracts of the 43rd Annual ICAAC ; September 14-17, 2003 ; Chicago : abstract : M-1024.
20. Flahaut M, Sanglard D, Monod M, Bille J, Rossier M. Rapid detection of Candida albicans in clinical samples by DNA aplification of common regions from Candida albicans - secreeted aspartic proteinase genes. J Clin Microbiol 1998 ; 36 : 395-401.
21. Sendid B, Tabouret M, Poirot JL, Mathieu D, Fruit J, Poulain D. New enzyme immunoassay for sensitive detection of circulating Candida albicans mannan and antimannan antibodies : useful combined test for diagnosis of systemic candidiasis. J Clin Microbiol 1999 ; 37 : 1510-7.
22. Pfaller MA, Messer SA, Bolmstrom A, Odds FC, Rex JH. Multisite reproductibility of Etest MIC methode of antifungal suceptibility testing of yeast isolates. J Clin Microbiol 1996 ; 34 : 1691-3.
23. Dismukes WE. Introduction of antifungal drugs. Clin Infect Dis 2000 ; 30 : 653-7.
24. Rex JH, Walsh TJ, Sobel DS, et al. Practice guidelines for the treatment of candididasis. Clin Infect Dis 2000 ; 30 : 662-78.